Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Compass Therapeutics, Inc.CMPX · Entity 5614 | Director | January 02, 2026 | January 05, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | EVP, Chief Financial Officer | June 08, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Compass Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2036-01-02 | Direct | 90,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 90,000 · Balance 90,000 F1: This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.
Emergent BioSolutions Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 374,083 |
Reported balance
After 2026-06-08 transaction · row 1
1 source rowRow 1 · 2026-06-08 · Tax withholding · Disposed 3,964 · Balance 374,083 F1: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CEB Inc.
Report date April 05, 2017 · Filed April 06, 2017
Section 16 reporting ended · disclosed 2017-04-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-04-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2017-04-05 · Exercise / conversion · Acquired 7,686 · Balance 45,538 F1: Represents the shares of common stock of CEB Inc. ("CEB") acquired upon vesting of the restricted stock units of CEB beneficially owned by the reporting person on the effective date of the merger ("Merger") described in the Agreement and Plan of Merger ("Merger Agreement") dated as of January 5, 2017, among Gartner, Inc. ("Gartner"), Cobra Acquisition Corp. and CEB ("Vested RSUs"). F2: Each PSU represented a right upon vesting (based on the achievement of performance goals at target performance) to receive one share of CEB's common stock. Row 2 · 2017-04-05 · Tax withholding · Disposed 1,253 · Balance 44,285 F3: Represents the number of shares of CEB common stock underlying the Vested PSUs withheld to satisfy tax withholding obligations related to the Vested PSUs. F4: The closing price on the New York Stock Exchange ("NYSE") of CEB common stock on April 3, 2017. Row 3 · 2017-04-05 · Disposition to issuer · Disposed 6,433 · Balance 37,852 F5: Represents the disposition pursuant to the Merger Agreement of the shares underlying the Vested PSUs, net of tax withholding. F6: Disposed of pursuant to the Merger Agreement in exchange for per share consideration of (a) $54.00 in cash and (b) 0.2284 of a share of common stock of Gartner. Gartner common stock had a market value of $108.70 per share based on the closing price on the NYSE on the last trading day immediately preceding the Merger (April 4, 2017). Row 4 · 2017-04-05 · Disposition to issuer · Disposed 37,852 · Balance 0 F7: Represents the number of shares of common stock of CEB beneficially owned by the reporting person immediately prior to the effectiveness of the Merger. F6: Disposed of pursuant to the Merger Agreement in exchange for per share consideration of (a) $54.00 in cash and (b) 0.2284 of a share of common stock of Gartner. Gartner common stock had a market value of $108.70 per share based on the closing price on the NYSE on the last trading day immediately preceding the Merger (April 4, 2017). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2017-04-05 | Direct | 0 |
Reported balance
After 2017-04-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-04-05 · Exercise / conversion · Disposed 23,435 · Balance 0 F8: Each restricted stock unit of CEB ("RSU") that did not vest at or before the effectiveness of the Merger was assumed by Gartner and converted into a restricted share unit payable in a number of shares of Gartner common stock, rounded up to the nearest whole share, equal to the product of (i) the applicable number of shares of CEB common stock subject to such award multiplied by (ii) the sum of (x) 0.2284 plus (y) a fraction resulting from dividing $54.00 by the closing price per share of Gartner common stock on the NYSE on the last trading day immediately preceding the closing date of the Merger ($108.70). F9: RSUs that were awarded on March 26, 2014, March 25, 2015, March 30, 2016 and March 15, 2017 and did not vest at or before the effectiveness of the Merger that rolled over into restricted share units of Gartner. F10: Pursuant to the Merger Agreement, on the effective date of the Merger, each outstanding RSU that did not vest before or in connection with the Merger rolled over into a restricted share unit of Gartner. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Expires 2017-04-05 | Direct | 0 |
Reported balance
After 2017-04-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-04-05 · Exercise / conversion · Disposed 7,686 · Balance 0 F2: Each PSU represented a right upon vesting (based on the achievement of performance goals at target performance) to receive one share of CEB's common stock. F11: Pursuant to the Merger Agreement, immediately prior to the consummation of the Merger, since certain performance goals were achieved at target performance, each outstanding PSU vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the shares of common stock of CEB Inc. ("CEB") acquired upon vesting of the restricted stock units of CEB beneficially owned by the reporting person on the effective date of the merger ("Merger") described in the Agreement and Plan of Merger ("Merger Agreement") dated as of January 5, 2017, among Gartner, Inc. ("Gartner"), Cobra Acquisition Corp. and CEB ("Vested RSUs").
F2: Each PSU represented a right upon vesting (based on the achievement of performance goals at target performance) to receive one share of CEB's common stock.
F3: Represents the number of shares of CEB common stock underlying the Vested PSUs withheld to satisfy tax withholding obligations related to the Vested PSUs.
F4: The closing price on the New York Stock Exchange ("NYSE") of CEB common stock on April 3, 2017.
F5: Represents the disposition pursuant to the Merger Agreement of the shares underlying the Vested PSUs, net of tax withholding.
F6: Disposed of pursuant to the Merger Agreement in exchange for per share consideration of (a) $54.00 in cash and (b) 0.2284 of a share of common stock of Gartner. Gartner common stock had a market value of $108.70 per share based on the closing price on the NYSE on the last trading day immediately preceding the Merger (April 4, 2017).
F7: Represents the number of shares of common stock of CEB beneficially owned by the reporting person immediately prior to the effectiveness of the Merger.
F8: Each restricted stock unit of CEB ("RSU") that did not vest at or before the effectiveness of the Merger was assumed by Gartner and converted into a restricted share unit payable in a number of shares of Gartner common stock, rounded up to the nearest whole share, equal to the product of (i) the applicable number of shares of CEB common stock subject to such award multiplied by (ii) the sum of (x) 0.2284 plus (y) a fraction resulting from dividing $54.00 by the closing price per share of Gartner common stock on the NYSE on the last trading day immediately preceding the closing date of the Merger ($108.70).
F9: RSUs that were awarded on March 26, 2014, March 25, 2015, March 30, 2016 and March 15, 2017 and did not vest at or before the effectiveness of the Merger that rolled over into restricted share units of Gartner.
F10: Pursuant to the Merger Agreement, on the effective date of the Merger, each outstanding RSU that did not vest before or in connection with the Merger rolled over into a restricted share unit of Gartner.
F11: Pursuant to the Merger Agreement, immediately prior to the consummation of the Merger, since certain performance goals were achieved at target performance, each outstanding PSU vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2021 Filed Feb 26, 2021 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,010 | $93.49 | $94,424.90 |
DisclosureSEC source: 0001367644-21-000041 · wf-form4_161437750812785.xml · nonDerivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,792 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000041 · wf-form4_161437750812785.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,802 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000041 · wf-form4_161437750812785.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,790 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,522 | $123.45 | $311,340.90 |
DisclosureSEC source: 0001367644-21-000010 · wf-form4_161309639586111.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,779 F2 · security: Represents shares of common stock withheld to pay taxes due upon vesting of the PSUs. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000010 · wf-form4_161309639586111.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,301 F1 · security: Consists of Performance Stock Units ("PSUs") previously granted on May 8, 2018 under the company's stock incentive plan as amended and restated. Each PSU represents the right to receive one share of common stock, which vested at a specified percentage based upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2020 fiscal year, as certified by the Compensation Committee following the performance period. On February 9, 2021, the Compensation Committee certified the achievement of the 2018-2020 PSUs at a payout factor of 150% of target resulting in the actual award of 7,486 shares of common stock, which is in excess of the 4,991 shares previously reported on May 10, 2018. F1 · shares: Consists of Performance Stock Units ("PSUs") previously granted on May 8, 2018 under the company's stock incentive plan as amended and restated. Each PSU represents the right to receive one share of common stock, which vested at a specified percentage based upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2020 fiscal year, as certified by the Compensation Committee following the performance period. On February 9, 2021, the Compensation Committee certified the achievement of the 2018-2020 PSUs at a payout factor of 150% of target resulting in the actual award of 7,486 shares of common stock, which is in excess of the 4,991 shares previously reported on May 10, 2018. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 728 | $79.25 | $57,694.00 |
DisclosureSEC source: 0001367644-20-000055 · wf-form4_158931486324853.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,806 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 02:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 610 | $59.91 | $36,545.10 |
DisclosureSEC source: 0001367644-20-000017 · wf-form4_158285639623403.xml · nonDerivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,534 F3 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 24,414 | $61.44 Strike: $61.44 | $1,499,996.16 |
DisclosureSEC source: 0001367644-20-000017 · wf-form4_158285639623403.xml · derivative · entry 4 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,735 Underlying: Common Stock · 24,414 shares Expires 2027-02-24 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 6,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000017 · wf-form4_158285639623403.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,144 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue for the three year period 2020 - 2022 fiscal years, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 6,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000017 · wf-form4_158285639623403.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,040 F1 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| May 08, 2019 Filed May 10, 2019 22:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 759 | $47.49 | $36,044.91 |
DisclosureSEC source: 0001567619-19-010458 · doc1.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,937 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,321 | $61.01 Strike: $61.01 | $1,239,784.21 |
DisclosureSEC source: 0001567619-19-005674 · doc1.xml · derivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,321 Underlying: Common Stock · 20,321 shares Expires 2026-02-25 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005674 · doc1.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,696 F3 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005674 · doc1.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,615 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| May 08, 2018 Filed May 10, 2018 21:56 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to Buy) · Derivative | 19,963 | $48.33 Strike: $48.33 | $964,811.79 |
DisclosureSEC source: 0001140361-18-022841 · doc1.xml · derivative · entry 4 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,963 Underlying: Common Stock · 19,963 shares Expires 2025-05-07 F4 · derivative.exercise_date: Vests in three equal installments on May 7, 2019, May 7, 2020 and May 7, 2021. Read SEC document |
| May 08, 2018 Filed May 10, 2018 21:56 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022841 · doc1.xml · nonDerivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,534 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| May 08, 2018 Filed May 10, 2018 21:56 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 1,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022841 · doc1.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,543 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| May 08, 2018 Filed May 10, 2018 21:56 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022841 · doc1.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,992 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 20:52 UTC | CEB Inc. CEB · Entity 177136 | Exercise / conversionPerformance Stock Units · Derivative | 7,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026161 · doc4.xml · derivative · entry 6 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,686 shares Expires 2017-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each PSU represented a right upon vesting (based on the achievement of performance goals at target performance) to receive one share of CEB's common stock. F11 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the consummation of the Merger, since certain performance goals were achieved at target performance, each outstanding PSU vested. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 20:52 UTC | CEB Inc. CEB · Entity 177136 | Exercise / conversionRestricted Stock Units · Derivative | 23,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026161 · doc4.xml · derivative · entry 5 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,435 shares Expires 2017-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit of CEB ("RSU") that did not vest at or before the effectiveness of the Merger was assumed by Gartner and converted into a restricted share unit payable in a number of shares of Gartner common stock, rounded up to the nearest whole share, equal to the product of (i) the applicable number of shares of CEB common stock subject to such award multiplied by (ii) the sum of (x) 0.2284 plus (y) a fraction resulting from dividing $54.00 by the closing price per share of Gartner common stock on the NYSE on the last trading day immediately preceding the closing date of the Merger ($108.70). F9 · shares: RSUs that were awarded on March 26, 2014, March 25, 2015, March 30, 2016 and March 15, 2017 and did not vest at or before the effectiveness of the Merger that rolled over into restricted share units of Gartner. F10 · derivative.exercise_date: Pursuant to the Merger Agreement, on the effective date of the Merger, each outstanding RSU that did not vest before or in connection with the Merger rolled over into a restricted share unit of Gartner. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 20:52 UTC | CEB Inc. CEB · Entity 177136 | Disposition to issuerCommon Stock | 37,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-026161 · doc4.xml · nonDerivative · entry 4 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F7 · shares: Represents the number of shares of common stock of CEB beneficially owned by the reporting person immediately prior to the effectiveness of the Merger. F6 · price: Disposed of pursuant to the Merger Agreement in exchange for per share consideration of (a) $54.00 in cash and (b) 0.2284 of a share of common stock of Gartner. Gartner common stock had a market value of $108.70 per share based on the closing price on the NYSE on the last trading day immediately preceding the Merger (April 4, 2017). Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 20:52 UTC | CEB Inc. CEB · Entity 177136 | Disposition to issuerCommon Stock | 6,433 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-026161 · doc4.xml · nonDerivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,852 F5 · shares: Represents the disposition pursuant to the Merger Agreement of the shares underlying the Vested PSUs, net of tax withholding. F6 · price: Disposed of pursuant to the Merger Agreement in exchange for per share consideration of (a) $54.00 in cash and (b) 0.2284 of a share of common stock of Gartner. Gartner common stock had a market value of $108.70 per share based on the closing price on the NYSE on the last trading day immediately preceding the Merger (April 4, 2017). Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 20:52 UTC | CEB Inc. CEB · Entity 177136 | Tax withholdingCommon Stock | 1,253 | $78.85 | $98,799.05 |
DisclosureSEC source: 0001209191-17-026161 · doc4.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,285 F3 · shares: Represents the number of shares of CEB common stock underlying the Vested PSUs withheld to satisfy tax withholding obligations related to the Vested PSUs. F4 · price: The closing price on the New York Stock Exchange ("NYSE") of CEB common stock on April 3, 2017. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 20:52 UTC | CEB Inc. CEB · Entity 177136 | Exercise / conversionCommon Stock | 7,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-026161 · doc4.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the shares of common stock of CEB Inc. ("CEB") acquired upon vesting of the restricted stock units of CEB beneficially owned by the reporting person on the effective date of the merger ("Merger") described in the Agreement and Plan of Merger ("Merger Agreement") dated as of January 5, 2017, among Gartner, Inc. ("Gartner"), Cobra Acquisition Corp. and CEB ("Vested RSUs"). F2 · price: Each PSU represented a right upon vesting (based on the achievement of performance goals at target performance) to receive one share of CEB's common stock. Read SEC document |
| March 27, 2017 Filed Mar 29, 2017 16:32 UTC | CEB Inc. CEB · Entity 177136 | Exercise / conversionRestricted Stock Units · Derivative | 2,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-023507 · doc4.xml · derivative · entry 5 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.expiration_date: N/A Read SEC document |
| March 27, 2017 Filed Mar 29, 2017 16:32 UTC | CEB Inc. CEB · Entity 177136 | Exercise / conversionRestricted Stock Units · Derivative | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-023507 · doc4.xml · derivative · entry 4 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,749 Underlying: Common Stock · 1,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.expiration_date: N/A Read SEC document |
| March 27, 2017 Filed Mar 29, 2017 16:32 UTC | CEB Inc. CEB · Entity 177136 | Exercise / conversionRestricted Stock Units · Derivative | 2,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-023507 · doc4.xml · derivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,102 Underlying: Common Stock · 2,051 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.expiration_date: N/A Read SEC document |
| March 27, 2017 Filed Mar 29, 2017 16:32 UTC | CEB Inc. CEB · Entity 177136 | Tax withholdingCommon Stock | 744 | $78.90 | $58,701.60 |
DisclosureSEC source: 0001209191-17-023507 · doc4.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,852 Read SEC document |
| March 27, 2017 Filed Mar 29, 2017 16:32 UTC | CEB Inc. CEB · Entity 177136 | Exercise / conversionCommon Stock | 6,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-023507 · doc4.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 16:17 UTC | CEB Inc. CEB · Entity 177136 | GrantRestricted Stock Units · Derivative | 7,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-021359 · doc4.xml · derivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,561 Underlying: Common Stock · 7,561 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: Restricted Stock Units vest equally in four increments in the following months: April 2018, March 2019, March 2020 and March 2021. F3 · derivative.expiration_date: N/A Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 16:33 UTC | CEB Inc. CEB · Entity 177136 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 2,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012721 · doc4.xml · derivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F2 · shares: The number of these Performance-Based Restricted Stock Units was adjusted from the target amount of 2,819 to reflect the actual performance in the three-year period beginning January 1, 2014 and ending December 31, 2016. F3 · derivative.expiration_date: N/A F2 · derivative.underlying_shares: The number of these Performance-Based Restricted Stock Units was adjusted from the target amount of 2,819 to reflect the actual performance in the three-year period beginning January 1, 2014 and ending December 31, 2016. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 16:33 UTC | CEB Inc. CEB · Entity 177136 | Exercise / conversionCommon Stock | 2,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012721 · doc4.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.